middle.news
Neurotech Advances Phase 3 ASD Trial, Cuts Loss 38%, Raises $3.75M
5:19pm on Wednesday 26th of August, 2026 AEST
•
Healthcare
Read Story
Neurotech Advances Phase 3 ASD Trial, Cuts Loss 38%, Raises $3.75M
5:19pm on Wednesday 26th of August, 2026 AEST
Key Points
86% revenue increase driven by R&D grants
Net loss narrowed to $6.54 million
Phase 3 'Beyond Harmony' trial initiated at Monash Children's Hospital
FDA clears IND for US clinical development
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurotech International (ASX:NTI)
OPEN ARTICLE